24.07.2015 • News

Crisis Hits Greek Chemical Demand

The ongoing financial turmoil in Greece has had a negative effect on demand for chemicals, Vasilis Gounaris, vice president of the Hellenic Association of Chemical Industries (HACI) and vice president of BASF Greece, told the London-based chemical news service ICIS.

In 2014, demand was at the same level as 2013 and showing signs of recovery. The problems that arose after that – rooted in the banking system – subsequently crushed it, Gounaris said, noting that restrictions on Greek banks are a drag on the industry’s import-dependent, mostly small- and medium-sized companies with combined annual turnover of €2 billion and about 17,000 employees.

Partially offsetting the negative impact of the bank closures that have affected cash flows, the executive noted that chemical companies “have had a long tradition of reliable transactions.” He acknowledged, however, that “some companies are well prepared to deal with capital controls, while others face at least short-term problems.”

Greek chemical companies look forward to the implementation of reforms that will “enable them to operate on a level playing field,” Gounaris remarked. When banking restrictions are lifted, he believes the markets will be able to recover – especially if the political situation stabilizes and Greece continues on a “European course.” He conceded, however, that business is likely to continue pointing downward into the first half of 2016.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

29 April 2026 | This webinar explores how chemical industry organizations can design a digital‑ and AI‑ready operating model focused on clarity, usability, and measurable value.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read